We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Committee Unanimously Supports Takeda’s New Antiviral
FDA Advisory Committee Unanimously Supports Takeda’s New Antiviral
The FDA’s Antimicrobial Drugs Advisory Committee gave Takeda’s investigational antiviral, maribavir, a unanimous thumbs-up yesterday in two 17-0 votes as a potential treatment for refractory human cytomegalovirus (HCMV) infections in post-transplant patients with or without genotypic resistance.